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In 1671 when Antony van Leeuwenhoek first spied “animal-
cules,” now known to us as single cell organisms, through his 
homemade microscope, he set into motion a centuries long 
scientific endeavor to discover, describe, catalogue and gain 
a deeper understanding of the vast microbial world that sur-
rounds us. This laid the groundwork for the development of 
the germ theory by Louis Pasteur and Robert Koch over the 
course of the 1860’s and 1870’s. Germ Theory, the theory that 
many diseases are caused by microbial agents, revolutionized 
medicine leading to many advances such as the disinfecting 
of wounds, the appreciation of the need for a sterile envi-
ronment during surgery, and in 1921 the fortuitous discovery 
of penicillin by Alexander Fleming. Germ theory also had a 
profound influence on the attitudes of medicine and society 
at large towards “germs.” Although only a tiny fraction of 
microbes are pathogenic, they became indelibly associated, 
both in the popular imagination and in medical practice, with 
sickness and disease. This focus on microbe pathogenicity has 
yielded tremendous benefits to public health, in fact antibiotics 
were among the primary drivers of rising life expectancy in 
developed countries in the mid twentieth century (Armstrong, 
1999), but antibiotics, for all their benefits, came with costs as 
well, namely their effect on the native flora. 
Discovery of the body’s native flora began in the mid 1880’s 
when an Austrian pediatrician, Theodore Escherich, observed 
the eponymously named Escherichia coli in the stool of healthy 
children. Discovery continued apace and the realization set in 
that there was a large, diverse, community of microbes that 
colonized the skin, nasal and oral cavities, and the urogenital 
and gastrointestinal tracts of healthy people, making up their 
native flora. As early as the 1970’s there was already an idea 
of the number of microbes, then estimated to number rough-
ly 1014, living primarily in the gastrointestinal tract, and some 
idea of ecology of this diverse community (Savage, 1977). Until 
relatively recently, it was assumed that the microbes living in 
the colon lived a largely commensal existence, dining on food 
indigestible to the human host but not interacting with the 
host in any meaningful way. With this understanding collateral 
damage to the gut bacteria because of antibiotics was no great 
concern, with the worst-case scenario being an unwanted 
bloom of C. Difficile. However, in recent years and particularly 
since the launch of the Human Microbiome Project, an entirely 
different picture has emerged, one that includes many symbi-
otic relationships between the native flora and the host, in 
fact so enmeshed is the host-symbiont relationship, that they 
have been described as one “supraorganism (Turnbaugh, et al., 
2007). This new understanding demands a closer look at the 
possible effects of antibiotics on our microbiome.
This paper will explore the possible link between antibiotics 
and obesity. First it will lay the groundwork with a thorough 
exploration of the literature linking the state of the micro-
biome to obesity as well as an understanding of the under-
lying mechanisms. Then it will consider the evidence that a 
disturbance of the microbiota through antibiotic treatment 
can cause obesity along with proposed causative mechanism. 
Finally, it will propose ways to mitigate the effects of the anti-
biotic treatment. 
Methods
Information for this paper was obtained primarily through on-
line searches utilizing google scholar as well as well as numerous 
databases accessed through Touro college’s library system.
Abstract
In recent years, science has made great strides in its understanding of the microbiome, discovering that it plays a role in 
regulating many body processes. One area of study is the microbiomes interaction and influence on host metabolic pro-
cesses. Studies using both mice and humans have established a clear correlation between obesity and the composition of 
the microbiome, identifying a microbiome unique to obese individuals. Furthermore, experiments with germ-free mice 
have shown that the microbiome effects host metabolism, causing germ free mice to increase in mass when inoculated 
with normal microbiota. Inoculation with microbiota from obese mice yielded greater increases in mass, showing the 
obesogenic effect of the microbiota. The mechanisms through which the microbiome can contribute to obesity are en-
hanced extraction of energy from food, and increased capacity for nutrient uptake in the gut, and alteration of metabolic 
pathways by suppressing fasting induced adipose factor and decreasing AMPK activity. Many of these pathways show 
increased activity in obese mice. The enhanced energy extraction coupled with greater deposition of fat mediated by 
altered metabolic pathways can contribute to obesity.
The role of the microbiota in obesity, combined with decades-old observations that antibiotics, particularly early in life, 
increased the weight of livestock, led to a hypothesis that antibiotics can disrupt the development of the microbiome, 
causing metabolic changes, leading to obesity. Recently, this hypothesis has been tested, both in studies utilizing mice, and 
in many epidemiological studies. This paper will evaluate the available evidence to determine if exposure to antibiotics 
early in life can lead to increased incidence of obesity later. 
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Definition of “Core Microbiome”
The first step to determining if obesity is associated with an 
altered microbiome is establishing the baseline values defining 
what a “normal” gut microbiome looks like. This task is compli-
cated by the wide diversity of gut microbial populations found 
across different geographical areas and cultures, and even within 
communities and cultures. In fact, in one study “there was not 
a single abundant (defined as >0.5% of the community) bacte-
rial species shared by all 154 individuals” involved in the study 
(Turnbaugh P. J., 2009) . However, if one looks at the microbiome 
on the level of phyla, a strong pattern begins to emerge, with 
bacteria from the phyla Firmicutes and Bacteriodetes repre-
senting, in one study, 92.6% of the microbiota (Ley, et al., 2006). 
These 2 phyla and their respective ratios can serve as one defi-
nition of a core microbiota.
Another way of defining the core microbiome is, rather than 
focusing on the species or phyla present, focusing on the var-
ious genes present. Various studies utilizing this methodology 
have found that regardless of the vast diversity of the microbial 
makeup of the gut flora, there exists a “wide array of shared mi-
crobial genes, comprising an extensive, identifiable ‘core micro-
biome’ at the gene, rather than at the organismal lineage, level” 
(Turnbough, et al., 2009). While both definitions are useful, this 
paper will primarily utilize the second definition of the micro-
biome as a set of genes rather than ratio of different bacterial 
phyla. The reason for this is that a focus on genes can better 
illuminate any products of the microbiome that may affect host 
metabolic pathways, possibly contributing to obesity. 
Association of Obesity with Altered Microbiome
Having established a baseline microbiome, we can now explore 
any obesity associated changes that may occur. First, we will ex-
plore the changes in the ratio of Firmicutes and Bacteroidetes 
associated with obesity.
  In one experiment, mice heterozygous for obesity ob/+ (due to 
a defective leptin gene) were mated producing litters consisting 
of a mix of obese (ob/ob) and lean (ob/+ and +/+) phenotypes. 
Microbial ecology in the gut, specifically the ratio of Firmicutes 
to Bacteroidetes, which is typically similar among members of 
a family living together, was found to be consistent in the het-
erozygous mothers as well as the ob/+ and +/+ children. In the 
homozygous ob/ob mice of the same litter however, a sharp 
increase in abundance of Firmicutes relative to Bacteroidetes 
was observed (Ley, et al., 2005). This shows a clear correlation 
between obesity and the composition of the gut microbiome.
In another experiment, 12 obese individuals were randomly 
placed on either a fat or carbohydrate restricted diet and their 
gut microbiota was monitored over the course of a year for any 
discernible shift in the microbiota as they lost weight. Initially, 
obese people had more firmicutes and fewer Bateroidetes than 
lean controls. However, over the course of the year as their 
weight dropped, the ratio of Firmicutes to Bacetoidetes began 
to more closely resemble a typical lean profile (Ley, et al., 2006). 
Together, these two studies, encompassing both mice and men 
and showing both an increase in abundance of Firmicutes as an 
obese phenotype was acquired in the mouse experiment and 
a decrease in its abundance as weight was lost in the human 
experiment, firmly establish that obesity is associated with an 
altered microbiome.
Can the Gut Microbiome Cause Obesity?
Having established a strong correlation between obesity and al-
tered gut microbial ecology, we can now explore the possibility 
that the microbiome can be a causative agent in obesity. 
There seems to be good experimental evidence, at least with 
mice, that this is the case.
In one experiment, mice were divided into three groups. One 
group was raised “Germ Free” meaning that their gut was ster-
ile. Another group consisted of regular, conventionally raised 
mice, and acted as a control. A third group was initially raised 
germ, free but subsequently inoculated with gut bacteria at 7-10 
weeks by spreading a suspension of cecal content from the con-
trol group mice on their fur. Comparison of germ free and regu-
lar mice at 8 to 10 weeks found that regular mice had 42% more 
body fat than their germ-free companions and had epidydimal 
fat pads weighing 47% more, all while eating 29% less food. After 
a 14-day colonization, a process known as conventionalization, 
the third group of mice experienced a dramatic 57% increase in 
total body fat and a 61% increase in epididymal fat pad weight 
all while their chow consumption decreased to that of the nor-
mal mice (Backed, et al., 2004). This experiment shows that gut 
microbiota has a powerful effect on metabolism and fat storage. 
The initial low-fat state of the germ-free mice even with their 
above average food intake and their dramatic increase in fat, 
even in the face of decreased chow consumption, as they were 
conventionalized, indicates that a normal microbiome plays a 
key role in regulating fat in mice. 
Having established the effects of a normal microbiome, let us ex-
amine the effects of an obese one. Toward this end, an experiment 
was constructed in which germ-free mice were colonized by ga-
vage (meaning they were fed by tube) with the cecal contents of 
either wild type +/+ or genetically obese ob/ob (leptin deficient) 
mice. In the 14-day period following the colonization food con-
sumption in the (ob/ob) and (+/+) transplanted groups was not 
statistically different (55.4±2.5g for ob/ob against 54.0±1.2g for 
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+/+) and they both ate the same type of chow (no difference in 
caloric density). Despite this, the mice colonized with ob/ob mi-
crobiota exhibited a significantly greater increase in body fat than 
those colonized with +/+ microbiota with the ob/ob colonized 
mice increasing body fat by 47±8.3% and the +/+ colonized mice 
increasing by just 27±3.6% (Turnbaugh,et al., 2006).  
The dramatic difference in body fat between the two groups 
strongly indicates that the obese microbiome causes greater 
adiposity, and gives rise to the possibility that the microbiome 
can play a role in its development.
Mechanisms of Microbiome Influence on Adiposity
The classic, somewhat simplistic understanding of the devel-
opment of obesity is to take the calories of the food eaten, 
subtract calories burned by both the basal metabolic rate and 
any additional energy expenditures for various activities, and 
assume that the remainder is stored as fat in adipose tissue 
throughout the body. Our exploration of the mechanisms 
through which the gut microbiota increase adiposity will illu-
minate several ways that this seemingly straightforward and 
commonsense equation can be altered.
One mechanism proposed is that all microbiomes increase the 
bodies capacity for energy harvest from food eaten by excret-
ing exoenzymes that break down polysaccharides that the host 
is unable to metabolize. Once degraded into monosaccharides 
and short chain fatty acids, both the bacteria and the host 
readily take up the product, accruing extra calories to the host 
from the same food. It is further hypothesized that the changed 
obese microbiome performs these tasks more efficiently ex-
tracting even more calories from the same unit of food with the 
host reaping some of the benefits. This hypothesis is buttressed 
by numerous lines of evidence.
The first of these is a simple comparison of the energy re-
maining in the feces of regular mice as opposed to genetically 
obese mice. Bomb calorimetry showed that ob/ob mice have 
significantly less energy remaining than regular mice, yielding 3.2 
kcal/g compared to 3.4 in regular mice (Turnbaugh, et al., 2006). 
This is simple, clear, empirical evidence that an obese microbi-
ome harvests more energy than a standard, lean microbiome.
Another line of evidence involves a genetic analysis of the mi-
crobiome, specifically of genes encoding enzymes that catalyze 
the breakdown of polysaccharides indigestible to their hosts. 
In one study, a sequencing of 18 Human microbiomes identified 
genes for 156 carbohydrate- active enzymes, which are enzyme 
families that break down carbohydrates, including 77 glycoside 
hydrolase, 21 carbohydrate-binding module, 35 glycosyltrans-
ferase, 12 polysaccharide lyase and 11 carbohydrate-esterase 
families. These genes consisted of fully 2.62±.013% of all the 
microbial genes sequenced, a higher percentage than any other 
identified group of genes. Furthermore, an analysis of lean and 
obese twins found that the obese twins had a microbiome that 
was significantly enriched in genes coding for carbohydrate, 
lipid, and amino acid metabolism as compared to that of their 
lean twins (Turnbough, et al., 2009). 
Mice studies have yielded similar results, with ob/ob mice 
having microbiomes containing more genes coding for various 
carbohydrate-active enzymes as compared with their lean lit-
termates. A predicted result of this would be an increased con-
centration of the products of bacterial fermentation of these 
polysaccharides, such as butyrate and acetate, in the cecum 
of the ob/ob mice. This prediction was borne out, with cecal 
butyrate concentration of obese mice double those of lean 
mice and acetate levels 20% higher (Turnbaugh, et al., 2006). 
Interestingly this same study also found a greater abundance 
of archaea in the obese mice than their lean counterparts. 
Archaea oxidize the hydrogen produced as a by-product 
of fermentation by gut bacteria, turning it into methane. By 
removing a product of the fermentation reaction, they in-
crease its efficiency, serving to further enhance energy ex-
traction by the obese microbiome. Indeed, in a study of mice 
colonized with archaea commonly found in the human gut, 
Methanobrevibactor smithii and B. thetaiotamicron, a signifi-
cant increase in the efficiency of bacterial polysaccharide fer-
mentation leading to an increase in adiposity in the mice was 
observed (Samuel & Gordon, 2006)
In addition to increasing energy extraction from food, there is 
also evidence that the microbiome increases the hosts capacity 
for uptake of nutrients in the gut. In one experiment, germ-free 
and conventionalized mice were fed a glucose solution.  After fif-
teen minutes, the level of glucose uptake was found to be twice 
as high in the conventionalized mice as in the germ-free ones 
(Backed, et al., 2004). Additionally, the microbiome is essential to 
the development of the capillary network to transfer these nu-
trients from the intestines to the hepatic portal vein. Germ-free 
mice were found to have arrested development of this capillary 
network, and upon conventionalization, developed it to normal 
levels within ten days (Stappenbeck & Hooper, 2002). 
These lines of evidence collectively paint a picture of a micro-
biome that extracts more energy from food by breaking down 
complex polysaccharides that the host is unable to metabolize 
on his own and amplifying the hosts ability to absorb the resul-
tant monosaccharides, providing one possible mechanism for 
the microbiome to contribute to obesity. 
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Another mechanism proposed is that the microbiome modifies 
cell signaling pathways to increase fat storage, that is, to direct 
more of the energy harvested toward adipocyte storage rath-
er than other metabolic functions. Two metabolic pathways are 
involved, one of which involves fasting-induced adipose factor 
(Fiaf) which is a lipoprotein lipase inhibitor (Backed, et al., 2004). 
Lipoprotein lipase facilitates deposition of fat in adipocytes. Fiaf, 
which inhibits it, is a crucial regulator of this process. Fiaf is pro-
duced by brown and white fat, the liver, and the intestine. The 
microbiome suppresses the production of Fiaf in the intestinal 
epithelium, thereby increasing the activity of lipoprotein lipases, 
resulting in more triglycerides being incorporated into adipocytes. 
Experimental evidence for this machanism comes from a study 
that compared regular germ-free mice, germ-free mice incapa-
ble of producing Fiaf (Fiaf-/-), and conventionalized mice both 
with and without the Fiaf gene. The regular germ free mice, 
as expected were the leanest. Germ free Fiaf-/- mice howev-
er, were found to have nearly the same amount of fat as their 
conventionalised wild type peers. Furthermore, a conventional-
ization of the germ free Fiaf knockout mice yielded a minimal 
increase in body fat of 10±8% versus 55±16% for the wild type 
germ free mice. Conventionalization of heterozygotes (Fiaf +/-) 
yielded an intermediate result, consistant with the hypothesis. 
Additionally comparison of mRNA of conventionalised and 
germ free wild type mice revealed camparitively less Fiaf ex-
pression in the small intestines of the the former, expression 
elswhere though was unaffected (Backed, et al., 2004). Other 
studies have had similar findings, including one that found that 
while regular germ free mice were resistant to obesity induced 
by consuming an “american diet” in their case chow with higher 
fat content and more easily  digested sugars, Fiaf -/- mice had 
lost this resistance (Backhed, et al., 2007).  These findings point 
to fasting induced adipose factor as a major component of the 
microbiomes contribution to adiposity. 
Another pathway involves levels of AMP-activated protein ki-
nase, or AMPK (Backhed, et al,. 2007). AMPK is a key enzyme 
regulating metabolism, serving as the lynchpin of a complex web 
of metabolic pathways maintaining proper ATP levels. AMPK 
ramps up energy production in response to metabolic stresses. 
It is triggered primarily, as its name indicates, by an increased 
ratio of AMP to ATP, but also by numerous other factors such as 
an elevated ratio of NAD to NADH, and the hormones leptin 
and adiponectin (Kahn, et al,. 2005) . The microbiome is thought 
to decrease AMPK activity, leading to lower energy expenditure, 
with more calories remaining to be deposited as fat.
Evidence for this mechanism is based on a number of obser-
vations. The first is that germ free mice were found, using an 
immunoblot assay, to have phospho-AMPK, which is the active 
form, at concentrations 40% percent greater than their regular 
peers in their gastrocnemeus muscles. Consistant with these 
findings AMP levels in the germ-free mice were foud to be 50% 
higher. Additionally, many other enzymes involved in the fatty 
acid oxidation pathway triggered by AMPK showed fluctuations 
consistant with increased fatty acid oxidation. In this pathway, 
AcetylCoA carboxylase converts Acetyl CoA to Malonyl CoA, 
Malonyl CoA inhibits carnitine-palmitoyl transferase-1 (Cpt1), 
which catalyzes the rate-limiting step for uptake of long chain 
fatty acids by mitochondria, AMPK phosphorylates AcetylCoA 
carboxylase, inhibiting it and thereby increasing fatty acid 
oxidation (Kahn, et al, 2005). A 43% increase in the levels of 
phosphorylated AcetylCoA carboxylase was found using an 
immunoblot assay and a 17% increase in the level of Cpt1 was 
found with a biochemichal assay, in germ free over that of reg-
ular mice,both consistant with increased fatty acid oxidation 
(Backhed, et al,. 2007). 
Collectively, these lines of evidence paint a picture of a microbi-
ome that acts on both sides of the energy equation, harvesting 
more energy from food through greater polysaccharidase ac-
tivity, conserving more of that energy through, and depositing a 
greater portion of it as fat. 
Can Antibiotics Contribute to Obesity?
Having gained some appreciation of the influence of our micro-
biota on our metabolism and its role in promoting adiposity, 
we can now explore the role of antibiotics on this complex 
system. Specifically, we will explore whether the disruption to 
the microbiota caused by antibiotics, particularly early in life, can 
affect the body mass of the host later in life by either promoting 
or inhibiting weight gain.
There is extensive evidence that antibiotics promote weight 
gain, from veterinary medicine, animal models, and epidemio-
logical studies. 
In the 1950’s Veterinary scientists showed that giving pigs (Taylor 
& Gordon, 1955) and other livestock (Jukes & Williams, 1953) 
sub-therapeutic doses of antibiotics increased their growth 
causing them to gain more weight without increasing feed 
consumption. It subsequently became common practice among 
farmers to mix low doses of antibiotics into the feed of pigs, 
cows, sheep, and poultry, increasing their weight, a practice that 
continues to this day. The effect on weight gain is significant, a 
meta-analysis of numerous studies gauging the weight boosting 
effects of adding antibiotics to feed in pigs found an increase in 
weight gain of up to 15% and an increase in feed efficiency (an 
industry term for amount of meat produced per unit of feed) of 
up to 6%. The strongest effects were found when the antibiotics 
were given from birth with lesser, though still significant effects 
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found if they were given at later dates (Hays, 1969).  Evidence 
that the weight gain is connected to disruption of the microbio-
ta comes from experiments with germ free chickens. Germ free 
chickens given feed containing antibiotics that had a growth pro-
moting effect on regular chickens showed no similar increase in 
growth from the treatment (Coates, 1963), indicating that the 
weight gain is a result of modulation of the microbiome. These 
veterinary studies on regular and germ free animals, combined 
with the everyday experience of farmers for the last 70 years 
provide one line of evidence that antibiotic use has a role in 
weight gain. Importantly, as the data showed, the effect is greatly 
magnified in early life, suggesting that the early microbiome may 
be particularly vulnerable to whatever disruption causes the 
weight gain, a theme that will be expanded on shortly.
More evidence comes from experiments with model organisms, 
namely Mus Musculus, the mouse. Additionally, these experi-
ments shed light on the magnified effects of antibiotics found 
in early life.
In one experiment the effects of sub-therapeutic antibiotic 
treatment (STAT) was tested on mice to attempt to replicate its 
observed effect on farm animals and gain some insight into its 
mechanisms. In the experiment mice were exposed, starting at 
weaning, to various common antibiotics by putting them in their 
drinking water at sub-therapeutic levels, and were compared 
to a control group using various metrics. After a seven-week 
exposure, the STAT mice were found to have greater fat mass 
than the control group as well as a significantly higher percent 
body fat. Curiously although fat mass was greater in the STAT 
mice, total mass was not significantly greater at seven weeks, 
though later measurements taken from 8 to 26 weeks did show 
increased mass in the STAT mice (Cho, et al., 2012).
Utilization of other metrics allows for a deeper understanding 
of the processes driving the adiposity of the STAT mice. One 
important measure taken was the level of Gastric Inhibitory 
Polypeptide (GIP). GIP, a hormone secreted by K cells in the 
small intestine, stimulates lipoprotein lipase activity, increasing 
fat storage and contributing to adiposity (Miyawaki, et al., 2002). 
GIP levels were found to be substantially elevated in STAT mice 
(39.1±2.5 pg/ml) compared to the controls (24.4±4.2 pg/ml). 
This provides a possible mechanism for the observed increase 
in adiposity.
Microarray analysis of differential gene expression in hepatic tis-
sue yielded deeper insights into the metabolic changes wrought 
by STAT. Comparison of STAT and control mice found upregula-
tion of pathways for lipogenesis and triglyceride synthesis in the 
STAT mice, further contributing to adiposity.
Examination of the gut bacteria in the STAT mice yielded fur-
ther insight. Although the overall number of bacteria did not 
change significantly, the composition of the microbiome did 
change, with the abundance of Firmicutes increasing relative to 
that of Bacteroidetes, which, as discussed earlier, is typical of 
obese microbiomes. Additionally, examination of the cecal con-
tents of the STAT mice found higher levels of butyrate and ace-
tate, suggesting increased energy capture through fermentation 
of complex carbohydrates indigestible to the mice, as discussed 
earlier. Supporting evidence came from metabolic cage exper-
iments showing no difference in caloric intake but a lower ca-
loric output in fecal pellets in STAT mice compared to controls 
(Cho, et al., 2012). 
Taken together, these measurements paint a picture of antibi-
otics changing the composition of the microbiome, leading to 
metabolic changes causing adiposity and weight gain, and suggest 
that perhaps antibiotics can contribute to obesity in humans as 
well.
Increased Effect in Early Life
Greater weight gain was observed in farm animals when STAT 
was started earlier in life. Mouse studies have explored the im-
portance of the timing of antibiotic exposure further, exper-
imentally confirming these observations and expanding upon 
them. They found that early life is a critical time in metabolic 
development and exposure to antibiotics at this sensitive stage 
can permanently alter host metabolism.
Evidence for these claims comes from an experiment comparing 
mice started on low dose penicillin (LDP) at weaning (LDP-w) to 
mice where LPD was started shortly before birth(LDP-b) so that 
the initial colonization with maternal microbiota would be altered. 
A control group was maintained that was not exposed at all. 
The experiment found that earlier administration of antibiotics 
did have amplified effects. The growth rate for LDP-b was great-
er than the control, the fat mass as well as the total mass of 
adult LDP-b male mice was greater than that of LDP-w mice and 
the control (Cox, et al., 2014), demonstrating enhanced effects 
of earlier antibiotic administration. Sexual dimorphism was ap-
parent in the results with the females experiencing lesser if any 
effects, a finding that remains unexplained. Metabolic differences 
between the LDP-b and LDP-w mice were found as well with 
the LDP-b mice having greater expression of genes involved in 
adipogenesis than LDP-w mice. 
The mammalian early microbiome is a dynamic, changing en-
vironment typically showing a pattern of succession as differ-
ent taxa first dominate then diminish (Pantoja-Feliciano, et al., 
2013). Altered representation of some of these taxa has been 
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associated with obesity (Kalliomaki, et al,. 2008). Typically, 
Lactobacillus is prominent in nursing animals, as was indeed the 
case with the controls. The LDP-b mice however, showed much 
lower levels of Lactobacillus, as well as other groups whose pop-
ulation typically peak in early life such as Candidatus Arthomitus 
and Allobaculum  (Cox, et al., 2014). Although the precise roles 
of these microbes are not known, their suppression by LDP and 
the dramatic phenotypic effects that follow suggest some role 
in metabolic development. 
In an experiment with worrying implications for human obesity, 
some LDP mice were switched to high fat diet at 17 weeks, and 
were compared to control groups with just a high fat diet or 
just LDP. The growth promoting effects of LDP were accentuat-
ed by the high fat diet producing fat and weight gain surpassing 
that produced by the high fat diet or LDP alone.
More worrying still, the metabolic effects of LDP lasted into 
adulthood even after treatment finished. Mice that received LDP 
for only four weeks after birth still experienced greater fat and 
total mass accumulation from 6-20 weeks. This weight gain per-
sisted even though the microbiota had appeared to normalize. 
Finally, to demonstrate that the metabolic and phenotypic 
changes observed were a result of an altered microbiota 
and not some direct effect of the penicillin, cecal microbiota 
were transferred from 18-week-old control and LDP mice to 
3 week germ-free mice. The mice inoculated with the LDP 
microbiota increased total mass and fat mass at a faster rate 
(.078 g/day total mass and .058 g/day fat mass faster) than 
those inoculated with the normal microbiota (Cox, et al., 
2014). 
These studies provide convincing evidence, as much as can be 
inferred from model organisms, that antibiotics contribute to 
obesity through disruption of the microbiota, and that early life 
is a particularly sensitive time when disruption of the developing 
microbiome can have long lasting metabolic effects.
Epidemiological Studies
The findings in model organisms that antibiotic exposure, par-
ticularly in early life, can lead to obesity, have important impli-
cations for human health. However, results in model organisms 
do not always translate into results in humans. Since ethical 
concerns preclude the types of randomized, controlled studies 
routinely performed with model organisms from being done on 
humans, we must rely on epidemiological evidence. Fortunately, 
there are a wealth of well-constructed epidemiological studies 
demonstrating that antibiotic exposure in infancy is correlated 
with obesity later in life.
In a study involving 28354 mother baby pairs from the Danish 
National Birth Cohort, antibiotic exposure in the first six 
months of life was correlated (with an odds ratio of 1.54, 
well above the threshold for showing correlation) with an in-
creased risk of being overweight at 7 years (Ajslev, et al., 2011). 
Supporting these findings are results from a study utilizing 
11532 children from the Avon Longitudinal Study of Parent and 
Children. This study examined antibiotic exposure during three 
early-life time windows, 6< months, 6-14 months, and 15-23 
months.  Exposure under six months was, once again, strongly 
correlated (p<.001) with increased body mass at 10, 20, and 
38 months. However, exposure from 6-14 months showed no 
effect and exposure at 15-24 showed a modest weight gain at 7 
years (Trasande, et al., 2013). A Canadian study combining data 
from health records and a Canadian longitudinal birth cohort 
study further bolstered these findings. The study found that 
children who received antibiotic treatment in the first year of 
life were more likely to be overweight at ages 9 and 12 than 
their untreated peers (32.4% overweight if exposed vs. 18.2% 
if not). Additionally, researchers noted a greater prevalence of 
elevated central adiposity, a precursor of metabolic syndrome, 
among the treated children (Azad, et al, 2014).  A longitudinal 
study in the USA (Bailey, et al., 2014)and a global cross sectional 
study (Murphy, et al., 2013) found similar results as well. Several 
the studies (Trasande, et al., 2013) (Murphy, et al., 2013) found a 
strong sexual dimorphism, with the effect much greater in boys, 
and nearly all the studies showed some difference between girls 
and boys, with the boys seeing greater weight gain than the 
girls, a finding that while replicated many times in both model 
organisms and in humans, has not been satisfactorily explained.
The collective weight of these epidemiological studies gives 
great credence to claims that antibiotics contribute to obesity.
Mitigating the Effects of Antibiotics
Even with all the evidence of detrimental side effect of antibi-
otics, stopping their use is obviously not an option. Antibiotics 
are a cornerstone of modern medicine, without which life ex-
pectancy would surely drop precipitously. However perhaps a 
bit of restraint in prescribing antibiotics to children is in order. 
Rates of antibiotic prescriptions in the USA are unnecessarily 
high, with some analyses finding that fully half of all antibiotic 
prescriptions written are unnecessary (Nyquist, et al., 1998). 
Although antibiotic prescription rates among children and ado-
lescents have dropped since that finding (Lee, et al., 2014), pre-
scription rates in the USA are still high compared to some other 
countries. In Sweden, for example, antibiotic use is 53% lower 
than in the USA (Ternhag & Hellman, 2010). This indicates that 
prescription levels can still be lowered significantly without ad-
versely effecting public health. While some antibiotic exposure 
may be unavoidable for many children, even merely reducing the 
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number of rounds of antibiotics they take reduces their chance 
of developing obesity later in life (Bailey, et al., 2014).
One final action possible to mitigate the obesogenic effects of 
antibiotics on children is to prescribe narrow spectrum anti-
biotics when possible. One study, despite finding significant 
correlation between broad-spectrum antibiotics in the first two 
years of life, found no such correlation for narrow-spectrum 
antibiotics (Bailey, et al., 2014).
Conclusions
In conclusion, the evidence for an obesogenic effect of early-life 
exposure to antibiotics is substantial and convincing. The many 
mouse studies demonstrating the influence of the microbiome 
on metabolism and its role in obesity give ample reason to sus-
pect that perturbations of the microbiome with antibiotics may 
have some effect on obesity. The evidence from farm animals, 
mice, and epidemiological studies serve to confirm that suspi-
cion, showing that antibiotic exposure in infancy contributes to 
one’s chances of developing obesity later in life.
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